Evidence map›Paper›PMID 36382217›Full record

ArticleBrain communications2022

Longitudinal evaluation of proton magnetic resonance spectroscopy metabolites as biomarkers in Huntington's disease.

Alexander J Lowe, Filipe B Rodrigues, Marzena Arridge, Enrico De Vita, Eileanoir B Johnson, Rachael I Scahill, Lauren M Byrne, Rosanna Tortelli, Amanda Heslegrave, Henrik Zetterberg and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. [Trinucleotide repeat disorders].Radiologie (Heidelberg, Germany) · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Alexander J LoweUCL Huntington's Disease Centre, UCL Queen Square Institute of Neurology, University College London, London WC1N 3BG, UK.
Filipe B RodriguesUCL Huntington's Disease Centre, UCL Queen Square Institute of Neurology, University College London, London WC1N 3BG, UK.
Marzena ArridgeLysholm Department of Neuroradiology, National Hospital for Neurology and Neurosurgery, London WC1N 3BG, UK.
Enrico De VitaLysholm Department of Neuroradiology, National Hospital for Neurology and Neurosurgery, London WC1N 3BG, UK.
Eileanoir B JohnsonUCL Huntington's Disease Centre, UCL Queen Square Institute of Neurology, University College London, London WC1N 3BG, UK.
Rachael I ScahillUCL Huntington's Disease Centre, UCL Queen Square Institute of Neurology, University College London, London WC1N 3BG, UK.
Lauren M ByrneUCL Huntington's Disease Centre, UCL Queen Square Institute of Neurology, University College London, London WC1N 3BG, UK.
Rosanna TortelliUCL Huntington's Disease Centre, UCL Queen Square Institute of Neurology, University College London, London WC1N 3BG, UK.
Amanda HeslegraveUK Dementia Research Institute at University College London, Fluid Biomarker Laboratory, London WC1E 6BT, UK.
Henrik ZetterbergUK Dementia Research Institute at University College London, Fluid Biomarker Laboratory, London WC1E 6BT, UK.
Edward J WildUCL Huntington's Disease Centre, UCL Queen Square Institute of Neurology, University College London, London WC1N 3BG, UK.
National Hospital for Neurology and Neurosurgery · GBUniversity College London · GBSahlgrenska University Hospital · SESt Thomas' Hospital · GBUK Dementia Research Institute · GB

Funding

Medical Research Council MR/M008592/1
6 · The paper itself

Abstract

Proton magnetic resonance spectroscopy is a non-invasive method of exploring cerebral metabolism. In Huntington's disease, altered proton magnetic resonance spectroscopy-determined concentrations of several metabolites have been described; however, findings are often discrepant and longitudinal studies are lacking. Proton magnetic resonance spectroscopy metabolites may represent a source of biomarkers, thus their relationship with established markers of disease progression require further exploration to assess prognostic value and elucidate pathways associated with neurodegeneration. In a prospective single-site controlled cohort study with standardized collection of CSF, blood, phenotypic and volumetric imaging data, we used 3 T proton magnetic resonance spectroscopy in conjunction with the linear combination of model spectra method to quantify seven metabolites (total

Indexed as

biomarkerscerebrospinal fluidHuntington’s diseasemagnetic resonance spectroscopy

Identifiers

PMID36382217
PMCPMC9665272
OpenAlexW4304731424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.